alzheimers - Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

FDA likely to approve Biogen’s aducanumab for Alzheimer’s disease after its review

There is a high unmet need for DMTs in AD as the current competitive landscape offers six medications that are aimed at treating the symptoms of the disease. Credit: pathdoc/Shutterstock.